PURPOSE: To assess whether the low incidence of severe neutropenia in castrated men with prostate cancer treated with docetaxel is the result of changes in systemic clearance. PATIENTS AND METHODS: A total of 10 noncastrated and 20 castrated men with prostate cancer were studied to achieve 80% power (α = .05) to detect at least a 25% change in the clearance of docetaxel. The erythromycin breath test was evaluated to determine hepatic activity of cytochrome P450 3A4 (CYP3A4), the main docetaxel-metabolizing enzyme. Additional studies were performed in rats and transfected cells overexpressing human or rodent transporters. RESULTS: Docetaxel clearance was increased by approximately 100% in castrated men and was associated with a two-fold reduction in area under the curve (P = .0001), although hepatic activity of CYP3A4 was unchanged (P = .26). In rats, castration was associated with higher uptake of docetaxel in the liver and a concurrent increase in the expression of rOat2 (Slc22a7), an organic anion transporter that regulates, in part, the transfer of docetaxel from the circulation into hepatocytes. CONCLUSION: It is recommended that castration- and/or hormone-related changes in the clearance of oncology drugs should be considered as a possible risk factor for treatment failure.
PURPOSE: To assess whether the low incidence of severe neutropenia in castrated men with prostate cancer treated with docetaxel is the result of changes in systemic clearance. PATIENTS AND METHODS: A total of 10 noncastrated and 20 castrated men with prostate cancer were studied to achieve 80% power (α = .05) to detect at least a 25% change in the clearance of docetaxel. The erythromycin breath test was evaluated to determine hepatic activity of cytochrome P450 3A4 (CYP3A4), the main docetaxel-metabolizing enzyme. Additional studies were performed in rats and transfected cells overexpressing human or rodent transporters. RESULTS:Docetaxel clearance was increased by approximately 100% in castrated men and was associated with a two-fold reduction in area under the curve (P = .0001), although hepatic activity of CYP3A4 was unchanged (P = .26). In rats, castration was associated with higher uptake of docetaxel in the liver and a concurrent increase in the expression of rOat2 (Slc22a7), an organic anion transporter that regulates, in part, the transfer of docetaxel from the circulation into hepatocytes. CONCLUSION: It is recommended that castration- and/or hormone-related changes in the clearance of oncology drugs should be considered as a possible risk factor for treatment failure.
Authors: Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Radka Vaclavikova; Pavel Soucek; Lenka Svobodova; Pavel Anzenbacher; Petr Simek; F Peter Guengerich; Ivan Gut Journal: Drug Metab Dispos Date: 2004-06 Impact factor: 3.922
Authors: René Bruno; Robert Olivares; Jocelyne Berille; Philip Chaikin; Nicole Vivier; Luz Hammershaimb; Gerald R Rhodes; James R Rigas Journal: Clin Cancer Res Date: 2003-03 Impact factor: 12.531
Authors: Sharyn D Baker; Ming Zhao; Ping He; Michael A Carducci; Jaap Verweij; Alex Sparreboom Journal: Anal Biochem Date: 2004-01-15 Impact factor: 3.365
Authors: Hossein Jadvar; Erik M Velez; Bhushan Desai; Lingyun Ji; Patrick M Colletti; David I Quinn Journal: J Nucl Med Date: 2019-03-29 Impact factor: 10.057
Authors: A J Armstrong; S Halabi; P Healy; W R Lee; B F Koontz; J W Moul; K Mundy; P Creel; S Wood; K Davis; M A Carducci; M Stein; C Hobbs; B Reimer; M Nguyen; M Anand; L Bratt; S Kim; P T Tran; D J George Journal: Prostate Cancer Prostatic Dis Date: 2016-01-12 Impact factor: 5.554
Authors: Marie-Rose B S Crombag; Aurelia H M de Vries Schultink; Jacobine G C van Doremalen; Hans-Martin Otten; Andries M Bergman; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema Journal: Drugs Aging Date: 2019-04 Impact factor: 3.923
Authors: Marit A C Vermunt; Lisa T van der Heijden; Jeroen J M A Hendrikx; Alfred H Schinkel; Vincent A de Weger; Eric van der Putten; Baukelien van Triest; Andries M Bergman; Jos H Beijnen Journal: Cancer Chemother Pharmacol Date: 2021-03-20 Impact factor: 3.333
Authors: Ricardo Fernandes; Sasha Mazzarello; Habeeb Majeed; Stephanie Smith; Risa Shorr; Brian Hutton; Mohammed Fk Ibrahim; Carmel Jacobs; Michael Ong; Mark Clemons Journal: Support Care Cancer Date: 2015-09-19 Impact factor: 3.603
Authors: Emmanuel S Antonarakis; Elisabeth I Heath; Edwin M Posadas; Evan Y Yu; Michael R Harrison; Justine Y Bruce; Steve Y Cho; Gregory E Wilding; Gerald J Fetterly; David G Hangauer; Min-Fun R Kwan; Lyn M Dyster; Michael A Carducci Journal: Cancer Chemother Pharmacol Date: 2013-01-13 Impact factor: 3.333